Last reviewed · How we verify
Rituximab, CMC544, Gemcitabine and Oxaliplatine
Rituximab, CMC544, Gemcitabine and Oxaliplatine is a Small molecule drug developed by The Lymphoma Academic Research Organisation. It is currently in Phase 1 development.
At a glance
| Generic name | Rituximab, CMC544, Gemcitabine and Oxaliplatine |
|---|---|
| Sponsor | The Lymphoma Academic Research Organisation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab, CMC544, Gemcitabine and Oxaliplatine CI brief — competitive landscape report
- Rituximab, CMC544, Gemcitabine and Oxaliplatine updates RSS · CI watch RSS
- The Lymphoma Academic Research Organisation portfolio CI
Frequently asked questions about Rituximab, CMC544, Gemcitabine and Oxaliplatine
What is Rituximab, CMC544, Gemcitabine and Oxaliplatine?
Rituximab, CMC544, Gemcitabine and Oxaliplatine is a Small molecule drug developed by The Lymphoma Academic Research Organisation.
Who makes Rituximab, CMC544, Gemcitabine and Oxaliplatine?
Rituximab, CMC544, Gemcitabine and Oxaliplatine is developed by The Lymphoma Academic Research Organisation (see full The Lymphoma Academic Research Organisation pipeline at /company/the-lymphoma-academic-research-organisation).
What development phase is Rituximab, CMC544, Gemcitabine and Oxaliplatine in?
Rituximab, CMC544, Gemcitabine and Oxaliplatine is in Phase 1.